8-K: Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance

Atara Biotherapeutics will implement a 1-for-25 reverse stock split effective June 20, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Atara Biotherapeutics has announced a 1-for-25 reverse stock split of its common stock.
• The reverse stock split is scheduled to take effect on June 20, 2024, at 12:01 a.m. Eastern Time.
• Trading on a split-adjusted basis will begin at market open on June 20, 2024.
• The primary reason for the reverse stock split is to regain compliance with the Nasdaq's minimum bid price requirement of $1.00 per share.
• The reverse stock split will reduce the number of outstanding shares from 122,606,575 to approximately 4,904,263, subject to adjustments for fractional shares.
• Proportionate adjustments will be made to outstanding equity awards, incentive plans, and pre-funded common stock warrants.
• Stockholders will receive cash in lieu of any fractional shares resulting from the split.
• The company's transfer agent, Computershare Trust Company, N.A., will act as the exchange agent for the reverse stock split.

Sentiment

Score: 4

Explanation: The announcement of a reverse stock split is generally viewed negatively by investors, as it often indicates a struggling stock price. While necessary for Nasdaq compliance, it doesn't inherently improve the company's fundamentals.

Positives

• The reverse stock split is a strategic move to regain compliance with Nasdaq listing requirements.
• The company is taking proactive steps to maintain its listing on the Nasdaq Global Select Market.
• The reverse stock split will not change the number of authorized shares or the par value per share.

Negatives

• The reverse stock split is often perceived negatively by investors as it can indicate a struggling stock price.
• The reduction in the number of outstanding shares may not necessarily increase the overall market capitalization of the company.

Risks

• The reverse stock split may not be sufficient to maintain the company's listing on the Nasdaq if the stock price does not remain above $1.00.
• The company's future performance and ability to raise capital may be impacted by the reverse stock split.
• The company's stock price may be volatile following the reverse stock split.

Future Outlook

The company anticipates that the reverse stock split will help maintain its listing on the Nasdaq Global Select Market, but there are no guarantees of future stock price performance.

Management Comments

• The reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Global Select Market, among other benefits.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices, particularly in the biotech sector where stock prices can be volatile.

Comparison to Industry Standards

• Many biotech companies facing similar challenges have implemented reverse stock splits to maintain their Nasdaq listing.
• For example, companies like Cassava Sciences and Ocugen have also conducted reverse stock splits to meet minimum bid price requirements.
• The 1-for-25 ratio is a relatively large split, indicating the severity of the stock price decline and the need for a significant adjustment.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant immediately after the split.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on the Nasdaq.

Next Steps

• The reverse stock split will be implemented on June 20, 2024.
• The company will monitor its stock price to ensure continued compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, ATRA, stock split, minimum bid price, Atara Biotherapeutics, equity awards, pre-funded warrants